Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Syneos Health, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Syneos Health, Inc. ("Syneos" or the "Company")(NASDAQ:SYNH) of the April 30, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you invested in Syneos stock or options between May 10, 2017 and February 27, 2019 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org.
The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased Syneos securities between May 10, 2017 and February 27, 2019 (the "Class Period"). The case, Murakami v. Syneos Health, Inc. et al, No. 19-cv-07377 was filed on 3/1/2019, and has been assigned to Michael A. Shipp.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Syneos’s internal control over financial reporting was inadequate; (2) concerns regarding Syneos’s internal control over financial reporting would result in heightened regulatory scrutiny and an SEC investigation into the Company’s revenue accounting policies, internal controls and related matters; and (3) as a result, Defendants’ statements about Syneos’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
On February 27, 2019, after market hours, the Company announced it was delaying the release of its Form 10-K for the year ended December 31, 2018 after the Securities and Exchange Commission (“SEC”) notified the Company it was investigating its revenue accounting policies and internal controls. The Company stated its management and Audit Committee were each conducting a review of the Company’s internal controls and/or accounting policies, amongst other things.
On this news, Syneos's share price fell from $52.01 per share on February 27, 2019 to a closing price of $41.77 on February 28, 2019: a $10.14 or a 19.69% drop.
Syneos Health, Inc. (SYNH)
* The submission of this form does not create an attorney-client relationship.
Filed on 02/28/2019
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Richard W. Gonnello email@example.com Phone (212) 983-9330 Fax (212) 983-9331